Year: 2018
Type: dissertation
Abstract: Invariant Natural Killer T (iNKT) cells are innate T cells that respond to lipid antigens presented by the molecule CD1d. Activated iNKT cells rapidly produce copious amounts of cytokines, activate/recruit other immune cells and have been implicated in tumour rejection and tumour immuno-surveillance. Here, our goal is to exploit iNKT cell antitumour properties in adoptive cell therapy and redirect their specificity towards tumour-associated antigens (TAAs) through T cell receptor (TCR) engineering. We hypothesize that TCR-engineered iNKT cells will be more effective than conventional CD8 T cells and provide long-term immunity.
Source: TSpace (University of Toronto)
Author: Juan Mauricio Umaña
Institution: University of Toronto
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2918109080
